Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | First analysis of VenDd +/- V for RRMM shows unprecedented reponse

Nizar Bahlis • 10 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Venetoclax
M15-645

Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, discusses the first analysis from M15-654 (NCT03314181), a phase I/II, non-randomized, multicenter study of venetoclax in combination with daratumumab and dexamethasone (VenDd), with or without bortezomib (V), in patients with relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Nizar Bahlis

Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023
Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea et al. • 15 Apr 2023
Updates in multiple myeloma
Nizar Bahlis et al. • 14 Apr 2023
1:53
Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM
Nizar Bahlis • 7 Dec 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals